AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18807108 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg phylloquinone
Number of subjects: 31
Study 18807108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 15861085 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumescent lidocaine injection into the neck (lidocaine 0.1%, NaHCO3 12.5 mEq/L, epinephrine 1:1,000,000, 7 mg/kg)
Number of subjects: 8
Study 15861085 — intervention group
Group type: COMPARATOR
Intervention: Tumescent lidocaine injection into the thighs (lidocaine 0.1%, NaHCO3 12.5 mEq/L, epinephrine 1:1,000,000, 7 mg/kg)
Number of subjects: 8
Study 15861085 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumescent lidocaine injection into the neck
Number of subjects: 8
Study 15861085 — intervention group
Group type: COMPARATOR
Intervention: Tumescent lidocaine injection into the thighs
Number of subjects: 8
Study 12830403 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 113
Study 12830403 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 113
Study 10378864 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta‐1a (Avonex) treatment for 104 weeks
Number of subjects: 301
Study 10378864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 10378864 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta‐1a (Avonex) treatment
Number of subjects: 301
Study 10378864 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CSF parameters (IgG index, kappa light chains, OCB)
Number of subjects: 301
Study 9017566 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched caseworkers (Anglo group)
Number of subjects: 610
Study 9017566 — intervention group
Group type: COMPARATOR
Intervention: Not matched caseworkers (Anglo group)
Number of subjects: 610
Study 9017566 — intervention group
Group type: COMPARATOR
Intervention: Matched and nonmatched subgroups (all ethnic groups)
Number of subjects: 610
Study 1658942 — intervention group
Group type: EXPERIMENTAL
Intervention: Logiparin 50 mg/kg body weight once daily for 7 days, starting 2 hours preoperatively.
Number of subjects: 210
Study 1658942 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 7 days, starting 2 hours preoperatively.
Number of subjects: 210
Study 30118625 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm presser
Number of subjects: 0
Study 30118625 — intervention group
Group type: COMPARATOR
Intervention: TFT
Number of subjects: 0
Study 30328725 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free tafluprost/timolol fixed combination (TTFC) administered in the evening (20:00) for 3 months
Number of subjects: 42
Study 30328725 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free tafluprost/timolol fixed combination (TTFC) administered in the morning (08:00) for 3 months
Number of subjects: 42
Study 30328725 — intervention group
Group type: COMPARATOR
Intervention: Preserved latanoprost monotherapy
Number of subjects: 42
Study 26383099 — intervention group
Group type: EXPERIMENTAL
Intervention: Insect therapy (5 crickets in a cage with sufficient fodder and a detailed instruction manual)
Number of subjects: 94
Study 26383099 — intervention group
Group type: EXPERIMENTAL
Intervention: Insect therapy
Number of subjects: 94
Study 26383099 — intervention group
Group type: COMPARATOR
Intervention: Control group (only health advice)
Number of subjects: 94
Study 24899596 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation (2710 mg EPA/day and 2040 mg DHA/day for one month)
Number of subjects: 48
Study 24899596 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 48
Study 22329674 — intervention group
Group type: EXPERIMENTAL
Intervention: pantoprazole 40 mg daily
Number of subjects: 10
Study 22329674 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 20398020 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prednisone comedication
Number of subjects: 210
Study 20398020 — intervention group
Group type: COMPARATOR
Intervention: Non-low-dose prednisone (control group)
Number of subjects: 210
Study 17993770 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 h i.v. infusion of active ghrelin
Number of subjects: 25
Study 15790912 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed patching for 3 hours
Number of subjects: 52
Study 15790912 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed patching for 6 hours
Number of subjects: 52
Study 15790912 — intervention group
Group type: COMPARATOR
Intervention: No patching (0 hours)
Number of subjects: 52
Study 11796537 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9795454 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-regurgitation formula (casein/whey ratio 80/20)
Number of subjects: 40
Study 9795454 — intervention group
Group type: COMPARATOR
Intervention: Regular adapted formula (casein/whey ratio 40/60)
Number of subjects: 40
Study 8568081 — intervention group
Group type: EXPERIMENTAL
Intervention: High level of child negative affect (NA)
Number of subjects: 39
Study 8568081 — intervention group
Group type: COMPARATOR
Intervention: No negative affect (NNA)
Number of subjects: 39
Study 2551805 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 2551805 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study 640917 — intervention group
Group type: EXPERIMENTAL
Intervention: Tests 1 through 12 (various intervals of 10, 20, 30, or 40 minutes between tests)
Number of subjects: 5
Study 640917 — intervention group
Group type: COMPARATOR
Intervention: Standard Reference (SR) test
Number of subjects: 5
Study 30647190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 30647190 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 301
Study 30647190 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 8 mg
Number of subjects: 301
Study 28401842 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-child attachment-based video-feedback intervention (8-week duration)
Number of subjects: 41
Study 28401842 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 41
Study 25778837 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental trait anxiety pre- and post-treatment
Number of subjects: 31
Study 25778837 — intervention group
Group type: COMPARATOR
Intervention: Parental anxiety
Number of subjects: 31
Study 24051110 — intervention group
Group type: EXPERIMENTAL
Intervention: SEMSA-C (Chinese version of the self-efficacy measures for sleep apnea questionnaire)
Number of subjects: 100
Study 21885885 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental PA intervention (8-week individualized counseling and community-based PA component)
Number of subjects: 96
Study 21885885 — intervention group
Group type: COMPARATOR
Intervention: Standard care (diabetes education program)
Number of subjects: 96
Study 21885885 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Standard care and Supplemental PA intervention)
Number of subjects: 96
Study 19969163 — intervention group
Group type: EXPERIMENTAL
Intervention: rMV (100Hz, 300-500 microm, in three 10-minute sessions a day for 3 consecutive days) applied to voluntary contracted quadriceps
Number of subjects: 60
Study 19969163 — intervention group
Group type: EXPERIMENTAL
Intervention: rMV (100Hz, 300-500 microm, in three 10-minute sessions a day for 3 consecutive days) applied to relaxed quadriceps
Number of subjects: 60
Study 19969163 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation (nonvibrated group)
Number of subjects: 60
Study 17391323 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS 5161 HCl 250 microg
Number of subjects: 40
Study 17391323 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS 5161 HCl 500 microg
Number of subjects: 40
Study 17391323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 14998738 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased perceived personal influence
Number of subjects: 47
Study 14998738 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation of failure
Number of subjects: 47
Study 11580151 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon continued for 1 more year with gradual reduction of the dose
Number of subjects: 57
Study 11580151 — intervention group
Group type: COMPARATOR
Intervention: Interferon stopped
Number of subjects: 57
Study 11580151 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon continued
Number of subjects: 57
Study 9578788 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPw-HB vaccine booster dose at 18 months of age
Number of subjects: 0
Study 9578788 — intervention group
Group type: COMPARATOR
Intervention: DTPw-HB vaccine
Number of subjects: 0
Study 8424283 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (GA) with halothane and opioids
Number of subjects: 20
Study 8424283 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia combined with regional anesthesia (RA) with epidural bupivacaine (0.25%) and adrenaline
Number of subjects: 20
Study 3475196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotiam in 2 doses of 2 g for 5 days
Number of subjects: 65
Study 3475196 — intervention group
Group type: COMPARATOR
Intervention: Cefotiam in 2 doses of 2 g only perioperatively
Number of subjects: 65
Study 3475196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone in a single dose of 2 g preoperatively
Number of subjects: 65
Study 3475196 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prophylaxis with 1 g ceftriaxone preoperatively
Number of subjects: 65
Study 30995643 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about HIV/AIDS transmission
Number of subjects: 346
Study 30995643 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of HIV/AIDS
Number of subjects: 346
Study 29022387 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum IS-10506 (1010 cfu/day)
Number of subjects: 22
Study 29022387 — intervention group
Group type: COMPARATOR
Intervention: Placebo (skim milk-Avicel)
Number of subjects: 22
Study 25848848 — intervention group
Group type: EXPERIMENTAL
Intervention: 550 mg NSAID + paracervical block (group 2)
Number of subjects: 75
Study 25848848 — intervention group
Group type: EXPERIMENTAL
Intervention: 550 mg NSAID + paracervical analgesic cream (group 3)
Number of subjects: 75
Study 25848848 — intervention group
Group type: COMPARATOR
Intervention: 550 mg NSAID (group 1)
Number of subjects: 75
Study 25848848 — intervention group
Group type: EXPERIMENTAL
Intervention: 550 mg NSAID + intrauterine analgesic instillation (group 4)
Number of subjects: 75
Study 23578600 — intervention group
Group type: EXPERIMENTAL
Intervention: CAS
Number of subjects: 254
Study 23578600 — intervention group
Group type: COMPARATOR
Intervention: CEA
Number of subjects: 254
Study 21282434 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose of sulfadoxine-pyrimethamine (25/1.25 mg/kg of body weight)
Number of subjects: 70
Study 21282434 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose of sulfadoxine-pyrimethamine (50/2.5 mg/kg of body weight)
Number of subjects: 70
Study 19174830 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A plus zinc
Number of subjects: 373
Study 19174830 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (including vitamin A and zinc)
Number of subjects: 373
Study 19174830 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A alone
Number of subjects: 373
Study 16924024 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with IGE
Number of subjects: 19
Study 16924024 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 19
Study 15368799 — intervention group
Group type: EXPERIMENTAL
Intervention: Family History Score (FHS) based on presence of coronary heart disease, hypertension, hypercholesterolaemia, and diabetes mellitus in first-degree relatives
Number of subjects: 1926
Study 15368799 — intervention group
Group type: EXPERIMENTAL
Intervention: Family History Score (FHS)
Number of subjects: 1926
Study 11401052 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 parts per billion SO2
Number of subjects: 24
Study 11401052 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 24
Study 9655010 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 152
Study 9655010 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 152
Study 8069645 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. caffeine
Number of subjects: 0
Study 8069645 — intervention group
Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 0
Study 2973693 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-treated recombinant DNA hepatitis B vaccine
Number of subjects: 0
Study 2973693 — intervention group
Group type: COMPARATOR
Intervention: Vaccine stored at 4 degrees C
Number of subjects: 0
Study 29675875 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care bundle (modulation of the infants' states, non‐nutritive sucking, facilitated tucking, and oral sucrose feeding)
Number of subjects: 65
Study 29675875 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control condition including routine procedures, positioning, and gentle touch)
Number of subjects: 65
Study 26827233 — intervention group
Group type: EXPERIMENTAL
Intervention: Long spine board (LSB)
Number of subjects: 0
Study 26827233 — intervention group
Group type: COMPARATOR
Intervention: Stretcher mattress
Number of subjects: 0
Study 25714528 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranilast Group (n=15)
Number of subjects: 29
Study 25714528 — intervention group
Group type: COMPARATOR
Intervention: Control Group (n=14)
Number of subjects: 29
Study 23275012 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM)
Number of subjects: 320
Study 23275012 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (WM)
Number of subjects: 320
Study 20697092 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with single-agent rituximab followed by 4 cycles of maintenance therapy every 2 months (prolonged exposure)
Number of subjects: 202
Study 20697092 — intervention group
Group type: COMPARATOR
Intervention: Observation (no further treatment after induction)
Number of subjects: 202
Study 18215332 — intervention group
Group type: EXPERIMENTAL
Intervention: One-year school-based exercise intervention program (40 minutes of general physical activity per school day, totaling 200 minutes/week)
Number of subjects: 53
Study 18215332 — intervention group
Group type: COMPARATOR
Intervention: General Swedish physical education curriculum (60 minutes/week)
Number of subjects: 53
Study 17015058 — intervention group
Group type: EXPERIMENTAL
Intervention: d-methamphetamine (0.25 mg/kg)
Number of subjects: 12
Study 17015058 — intervention group
Group type: EXPERIMENTAL
Intervention: d-methamphetamine (0.5 mg/kg)
Number of subjects: 12
Study 17015058 — intervention group
Group type: EXPERIMENTAL
Intervention: racemic methamphetamine (0.5 mg/kg)
Number of subjects: 12
Study 17015058 — intervention group
Group type: EXPERIMENTAL
Intervention: l-methamphetamine (0.5 mg/kg)
Number of subjects: 12
Study 17015058 — intervention group
Group type: EXPERIMENTAL
Intervention: l-methamphetamine (0.25 mg/kg)
Number of subjects: 12
Study 17015058 — intervention group
Group type: EXPERIMENTAL
Intervention: racemic methamphetamine
Number of subjects: 12
Study 17015058 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 14551525 — intervention group
Group type: EXPERIMENTAL
Intervention: Early statin therapy started before discharge from hospital after an acute coronary syndrome
Number of subjects: 0
Study 14551525 — intervention group
Group type: EXPERIMENTAL
Intervention: Early statin therapy
Number of subjects: 0
Study 9613022 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive feedback on diagnostic measure
Number of subjects: 192
Study 9613022 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative feedback on diagnostic measure
Number of subjects: 192
Study 9613022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambiguous feedback on diagnostic measure
Number of subjects: 192
Study 8178906 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic ethinyl estradiol/norgestimate
Number of subjects: 0
Study 8178906 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic ethinyl estradiol/norgestimate
Number of subjects: 0
Study 8178906 — intervention group
Group type: EXPERIMENTAL
Intervention: Both monophasic and triphasic ethinyl estradiol/norgestimate
Number of subjects: 0
Study 2491867 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue-type plasminogen activator (rt-PA) 100 mg
Number of subjects: 171
Study 2491867 — intervention group
Group type: COMPARATOR
Intervention: Intravenous streptokinase 1.5 million units
Number of subjects: 171
Study 184771 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid therapy (dexamethasone)
Number of subjects: 143
Study 184771 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-antibiotic preparation
Number of subjects: 143
Study 184771 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (various formulations)
Number of subjects: 143
Study 184771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 31533704 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive outcome
Number of subjects: 395
Study 31533704 — intervention group
Group type: COMPARATOR
Intervention: Industry funding disclosure
Number of subjects: 395
Study 31533704 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative outcome
Number of subjects: 395
Study 27562036 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior-based sexual assault prevention intervention (empowerment, gender relations, self-defense for girls; healthy gender norms for boys)
Number of subjects: 5686
Study 27562036 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior-based sexual assault prevention intervention
Number of subjects: 5686
Study 27562036 — intervention group
Group type: COMPARATOR
Intervention: Health and hygiene curriculum (control group)
Number of subjects: 5686
Study 23594381 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention supplemented with SMS, including access to a tailor-made interactive website and periodic updates with school and leisure activities.
Number of subjects: 0
Study 23594381 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what the control entails).
Number of subjects: 0
Study 21148045 — intervention group
Group type: COMPARATOR
Intervention: Oral bosutinib 100 mg alone
Number of subjects: 0
Study 21148045 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bosutinib 100 mg with ketoconazole 400 mg
Number of subjects: 0
Study 19824222 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesofensine 0.25 mg
Number of subjects: 203
Study 19824222 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesofensine 0.5 mg
Number of subjects: 203
Study 19824222 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesofensine 1.0 mg
Number of subjects: 203
Study 19824222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 17679042 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 mg
Number of subjects: 20
Study 17679042 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 40 mg
Number of subjects: 20
Study 17679042 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg
Number of subjects: 20
Study 17679042 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 80 mg
Number of subjects: 20
Study 17679042 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 40 mg (second study)
Number of subjects: 20
Study 17679042 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg (second study)
Number of subjects: 20
Study 17679042 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg (second study)
Number of subjects: 20
Study 17679042 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 160 mg (second study)
Number of subjects: 20
Study 15060765 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseptic-coated catheter (ACC)
Number of subjects: 397
Study 15060765 — intervention group
Group type: COMPARATOR
Intervention: Standard non-coated catheter (NCC)
Number of subjects: 397
Study 11457746 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 37
Study 11457746 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 37
Study 9884850 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental spinal anaesthesia (bupivacaine 0.5% plain)
Number of subjects: 43
Study 9884850 — intervention group
Group type: COMPARATOR
Intervention: Single-dose spinal anaesthesia (2.5 mL of bupivacaine 0.5% plain)
Number of subjects: 43
Study 9884850 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (fentanyl, thiopentone, atracurium, enflurane, N2O/O2)
Number of subjects: 43
Study 7741492 — intervention group
Group type: EXPERIMENTAL
Intervention: imipenem/cilastatin
Number of subjects: 50
Study 7741492 — intervention group
Group type: COMPARATOR
Intervention: ceftriaxone/gentamicin
Number of subjects: 50
Study 2210673 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg/day)
Number of subjects: 80
Study 2210673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 778366 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ampicillin and gentamicin therapy with intrathecal administration of gentamicin
Number of subjects: 117
Study 778366 — intervention group
Group type: COMPARATOR
Intervention: Combined ampicillin and gentamicin therapy without intrathecal administration of gentamicin
Number of subjects: 117
Study 778366 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 117
Study 778366 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors
Number of subjects: 117
Study 30636504 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (8 or 12 mg according to weight)
Number of subjects: 82
Study 30636504 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 82
Study 30636504 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Number of subjects: 82
Study 30636504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 27859267 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 20 mg
Number of subjects: 10